Fact CheckerSign in

NCT05456893Recruiting

A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies

A Multicentre Prospective Longitudinal Observational Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies

Source: ClinicalTrials.gov · Last updated 6 May 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

UC is a chronic, idiopathic form of intestinal inflammatory disease (IBD) that affects the colon, most commonly afflicting adults aged 30-40 years and resulting in disability and lower quality of life (1). It is characterized by relapsing and remitting mucosal inflammation, starting in the rectum and extending to proximal segments of the colon. Although biologic therapies have provided clinical benefits to patients, these goals are still poorly met, due to the limited knowledge of the underlying mechanisms of immunopathology and the lack of predictive biomarkers that would allow proper patient stratification. The hypothesis of this study is that by identifying new biomarkers in blood, stool and tissue that (i) predict response (or non-response) to therapy prior to the start of treatment and (ii) predict response to therapy in the early phase of treatment will allow to find the right treatment for the right patient (personalized medicine).

Status (registry)
Recruiting
Study type
Observational
Enrollment
95 (estimated)
First submitted
30 Jun 2022
Start date
28 Jul 2022
Primary completion date
9 Sept 2027
Lead sponsor
Central Hospital, Nancy, France
NCT number
NCT05456893

What you commit to

  • Study type: Observational
  • Planned participants: 95
  • From 28 Jul 2022 to the primary completion date, 9 Sept 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Diagnosis of indeterminate colitis, microscopic colitis, ischaemic colitis, infectious colitis, radiation colitis
  • Absolute contraindications to endoscopy procedures or complication during previous endoscopy
  • Indication for surgery for UC
  • Rectal topical therapy (enemas or suppositories) ≤ 2 weeks prior to baseline
  • Treatment with \> 20 mg prednisone within 3 weeks prior to baseline

Other illness

  • Bleeding disorders
  • Person deprived of liberty for judicial or administrative decision, person under psychiatric care as referred in articles L. 3212-1 and L. 3213-1

Lab values

  • Anaemia (haemoglobin \< 10 g/dl) at baseline

Other

  • Any circumstances which could contradict a study participation and lead the Investigator to assess the patient as unsuitable for study participation for any other reason
  • Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the Public Health Code:
    • Pregnant, parturient or breastfeeding woman
    • Minor person (non-emancipated)
    • Adult person under legal protection (any form of public guardianship)
    • Adult person incapable of giving consent and not under legal protection

Who the study is looking for

  • Male and female patients ≥ 18 years of age (at the time of signing the ICF)
  • Established diagnosis of ulcerative colitis with a minimum disease duration of 3 months
  • Moderate to severe active UC defined by Mayo Score ≥ 6
  • Moderate to severe active UC defined by endoscopy score of ≥2
  • Indication to start any biological or small molecule agent (anti-TNF, anti- IL12/23, anti-integrin and JAK-inhibitors)
  • In case of treatment with corticosteroid: stable dose for at least 3 weeks prior to baseline, dosage ≤ 20 mg prednisone
  • Indication for an endoscopy for the assessment of disease activity as for standards of care and current guidelines
  • Able to comply with the study procedures
  • Person affiliated to or beneficiary of a social security plan
  • Person informed about study organization and able to sign informed consent form

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Central Hospital
Coordinator of this site? Confirm its status
NancyFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.